Epics Therapeutics
Founded 2018 · 30 employees on LinkedIn · 2 known investors
EPICS Therapeutics develops RNA epigenetics-based cancer treatments, focusing on METTL3 inhibitors for cancers including non-small cell lung cancer, pancreatic cancer, ovarian cancer, and colorectal cancer where existing therapies are insufficient.
Investors · 2
Frequently asked questions
- What does Epics Therapeutics do?
- EPICS Therapeutics develops RNA epigenetics-based cancer treatments, focusing on METTL3 inhibitors for cancers including non-small cell lung cancer, pancreatic cancer, ovarian cancer, and colorectal cancer where existing therapies are insufficient.
- Who are Epics Therapeutics's investors?
- Epics Therapeutics's investors include Fund+, Newton Biocapital.